Cecilia Camarda

Palermo, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy
Published: July 23, 2026

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy
Published: March 18, 2026

EEG recording during visual aura in migraine: Results by quantitative analysis.

EEG recording during visual aura in migraine: Results by quantitative analysis.

Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Published: February 01, 2026

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Journal: The journal of headache and pain
Published: December 20, 2025

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study.

Journal: The journal of headache and pain
Published: December 20, 2025

Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE).

Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE).

Journal: The journal of headache and pain
Published: July 28, 2025

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures.

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures.

Journal: The journal of headache and pain
Published: April 20, 2025

A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).

A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).

Journal: Journal of neurology
Published: March 15, 2025

The Impact of COVID-19 on Migraine: The Patients' Perspective.

The Impact of COVID-19 on Migraine: The Patients' Perspective.

Journal: Life (Basel, Switzerland)
Published: October 08, 2024

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.

Journal: Neurology and therapy
Published: August 06, 2024

Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine.

Beyond Pain: The Effects of OnabotulinumtoxinA Therapy on Sensitization and Interictal Symptoms in Chronic Migraine.

Journal: Toxins
Published: March 13, 2024

The Clinical Relevance of Artificial Intelligence in Migraine.

The Clinical Relevance of Artificial Intelligence in Migraine.

Journal: Brain sciences
Published: December 22, 2023
Showing 1-12 of 38

Last Updated: 09/26/2026